BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11815730)

  • 41. Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism.
    Zou S; McDow AD; Saeed Z; Hou T
    Cureus; 2023 Jan; 15(1):e33384. PubMed ID: 36751230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor].
    Amosenko FA; Brzhezovskiĭ VZh; Liubchenko LN; Shabanov MA; Kozlova VM; Vanushko VE; Kazubskaia TP; Gar'kavtseva RF; Kalinin VN
    Genetika; 2003 Jun; 39(6):847-54. PubMed ID: 12884527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.
    Grey W; Hulse R; Yakovleva A; Genkova D; Whitelaw B; Solomon E; Diaz-Cano SJ; Izatt L
    Endocr Pathol; 2017 Mar; 28(1):41-48. PubMed ID: 27704398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What Is the Malignancy Risk in Neurofibromatosis Type 1?
    Evans DG
    J Clin Oncol; 2016 Jun; 34(17):1967-9. PubMed ID: 27001592
    [No Abstract]   [Full Text] [Related]  

  • 46. Not Only
    Castroneves LA; Mangone FRR; Lerario AM; da Cunha Mercante AM; Batista RL; Barros LRC; Ferreira CV; Farias EC; Vanderlei FAB; Maia AL; Nagai MA; Jorge AAL; Hoff AO
    J Endocr Soc; 2024 Apr; 8(6):bvae059. PubMed ID: 38655100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrated proteogenomic characterization of medullary thyroid carcinoma.
    Shi X; Sun Y; Shen C; Zhang Y; Shi R; Zhang F; Liao T; Lv G; Zhu Z; Jiao L; Li P; Xu T; Qu N; Huang N; Hu J; Zhang T; Gu Y; Qin G; Guan H; Pu W; Li Y; Geng X; Zhang Y; Chen T; Huang S; Zhang Z; Ge S; Wang W; Xu W; Yu P; Lu Z; Wang Y; Guo L; Wang Y; Guo T; Ji Q; Wei W
    Cell Discov; 2022 Nov; 8(1):120. PubMed ID: 36344509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
    Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Thyroid C cells and their pathology: Part 1: normal C cells, - C cell hyperplasia, - precursor of familial medullary thyroid carcinoma].
    Ting S; Synoracki S; Schmid KW
    Pathologe; 2015 May; 36(3):246-53. PubMed ID: 25898937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Non-neoplastic hypercalcitoninemia. Pathological anatomy].
    Saint-André JP; Guyétant S
    Ann Endocrinol (Paris); 1996; 57(1):23-6. PubMed ID: 8734285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1.
    Segni M; Massa R; Bonifacio V; Tartaglia F; Pucarelli I; Marzullo A; Pasquino AM
    Horm Res; 2001; 56(1-2):63-6. PubMed ID: 11815730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes.
    Ercolino T; Lai R; Giachè V; Melchionda S; Carella M; Delitala A; Mannelli M; Fanciulli G
    Gene; 2014 Feb; 536(2):332-5. PubMed ID: 24361808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
    Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
    Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.
    Saggiorato E; Rapa I; Garino F; Bussolati G; Orlandi F; Papotti M; Volante M
    J Mol Diagn; 2007 Apr; 9(2):214-9. PubMed ID: 17384213
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemistry of medullary thyroid carcinoma and C-cell hyperplasia by an affinity-purified anti-human calcitonin antiserum.
    Hayashida CY; Alves VA; Kanamura CT; Ezabella MC; Abelin NM; Nicolau W; Bisi H; Toledo SP
    Cancer; 1993 Aug; 72(4):1356-63. PubMed ID: 8339225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
    Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.